Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 41.7% from a year ago

Total equity stood at $60.18M at the end of Q1 FY2026, down 41.7% from a year earlier and down 12.3% from the prior quarter. Over 3 fiscal years it compounded at -29.4% a year.

Context

  • Total equity amounted to 50.3% of total assets at the end of Q1 FY2026, down 22.7 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -41.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$60.18M-12.3% QoQ
Last fiscal yearDec 2025
$68.64M-47.8% YoY
Year agoMar 2025
$103.18M-41.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.7%——
1 year-47.8%——
3-year CAGR-29.4%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
68.64M USD
Year-over-year change
-47.8%
4-year CAGR
-30.0%

Total Equity vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -41.7% is the 8th highest of 11, against a peer median of +6.8%.
  • Total equity amounts to 50.3% of total assets for PRLD, versus a peer median of 59.5%.
PRLD Competitors
Total Equity for PRLD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$206.52B USD+493455.8%+25.8%96.1%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$136.64M USD+405.4%+102.0%93.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$116.59M USD+24.6%-41.4%37.0%
TNYATenaya Therapeutics, Inc.Mar 2026$106.19M USD-11.1%-20.3%78.6%
CRBUCaribou Biosciences, Inc.Mar 2026$102.02M USD-53.0%-25.9%68.5%
AVTXAvalo Therapeutics, Inc.Mar 2026$68.32M USD-44.3%—68.4%
PRLDPrelude Therapeutics IncorporatedMar 2026$60.18M USD-41.7%-29.4%50.3%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$50.97M USD+202.3%+6.5%50.6%
PYXSPyxis Oncology, Inc.Mar 2026$31.27M USD-69.7%-30.8%48.6%
IVAInventiva S.A.Dec 2025-€29.04M EUR+72.8%—11.7%
FHTXFoghorn Therapeutics Inc.Mar 2026-$76.41M USD-23.9%—34.4%
Peer median (excluding PRLD) —+6.8%-20.3%59.5%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents31.83M30.61M25.29M12.47M35.26M
Short-term Investments259.41M171.12M207.64M121.14M67.96M
Net Receivables00000
Inventory00000
Other Current Assets02.65M2.65M2.28M2.48M
Total Current Assets295.12M204.38M235.59M135.9M105.69M
Property, Plant & Equipment (Net)5.64M6.7M37.74M35.47M32.28M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets4.35M9.42M4.34M4.15M3.35M
Total Non-current Assets9.98M16.12M42.08M39.62M35.62M
Total Assets305.1M220.5M277.67M175.52M141.32M
Account Payables7.84M6.78M4.58M7.73M3.98M
Short-term Debt00000
Tax Payables00000
Deferred Revenue000033.73M
Other Current Liabilities5.01M6.21M6.61M9.79M5.4M
Total Current Liabilities19.2M21.7M21.83M25.64M52.99M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.8M
Other Non-current Liabilities03.36M3.34M3.09M2.84M
Total Non-current Liabilities03.36M18.75M18.42M19.68M
Total Liabilities19.2M25.06M40.58M44.06M72.68M
Common Stock5K5K5K5K5K
Retained Earnings(219.12M)(334.56M)(456.39M)(583.56M)(683.06M)
Accumulated OCI(711K)(1.69M)223K35K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity285.9M195.44M237.09M131.46M68.64M
Total Debt1.74M1.83M16.89M18.03M17.79M
Net Debt(30.09M)(28.77M)(8.4M)5.55M(17.47M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.